CONGRESS COVERAGE ASCO/EHA 2021 – Focus on Multiple Myeloma
The latest therapeutic developments in multiple myeloma – how will they change our approach to treatment patterns?
June 23, 2021
Faculty Chair
María Victoria Mateos, MD, PhD
University of Salamanca, Spain
Faculty Members
Irene Ghobrial, MD
Dana-Farber Cancer Institute, Boston, MA, US
Niels van de Donk, MD, PhD
Amsterdam University Medical Center, Amsterdam, the Netherlands
Mohamad Mohty, MD, PhD
Saint-Antoine Hospital and Sorbonne University, Paris, France
Sagar Lonial, MD, FACP
Emory University School of Medicine, Atlanta, GA, US
Hermann Einsele, MD, FRCP
Medizinische Klinik und Poliklinik II, Würzburg, Germany
Gareth Morgan, MD, PhD
NYU Langone Medical Center, New York, NY, US
REPORT TOPICS
- First Line (1): Smoldering and Transplant-Ineligible Multiple Myeloma
- First Line (2): Induction in Transplant-Eligible Multiple Myeloma
- First Line (3): Maintenance and MRD
- R/R MM: First and Second Relapse
- Triple-Refractory R/R MM: Novel Agents
- Triple-Refractory R/R MM: Antibodies and Bispecifics
- Triple-Refractory R/R MM: CAR Ts
